Diseases, Conditions, Syndromes

Scientists identify how SARS-CoV-2 spreads in the Middle East

Understanding the global transmission of SARS-CoV-2 is critical for rapidly containing and handling the virus, especially as new variants and mutations of concern emerge. Certain regions in the world, including the Middle ...

Medications

New drug shows promise against toxoplasmosis

Findings from a new University of Kentucky College of Medicine study published in the Journal of Biological Chemistry May 28 may lead to a new treatment against Toxoplasma gondii, the parasite that causes toxoplasmosis.

Medical research

What would it take to set up an African drug discovery ecosystem?

Africa has great potential for drug discovery. The continent has natural resources, indigenous knowledge and human capacity. And it has the need: it bears more than 20% of the global disease burden. There are many internationally ...

Medications

Technology assesses effectiveness and safety of drug targets

Researchers have boosted pioneering technology to show whether potential treatments are worth progressing into human trials, in a game-changing move that could dramatically reduce the high failure rates in drug discovery ...

page 1 from 29

Drug discovery

In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are discovered and/or designed.

In the past most drugs have been discovered either by identifying the active ingredient from traditional remedies or by serendipitous discovery. A new approach has been to understand how disease and infection are controlled at the molecular and physiological level and to target specific entities based on this knowledge.

The process of drug discovery involves the identification of candidates, synthesis, characterization, screening, and assays for therapeutic efficacy. Once a compound has shown its value in these tests, it will begin the process of drug development prior to clinical trials.

Despite advances in technology and understanding of biological systems, drug discovery is still a lengthy, "expensive, difficult, and inefficient process" with low rate of new therapeutic discovery. Information on the human genome, its sequence and what it encodes has been hailed as a potential windfall for drug discovery, promising to virtually eliminate the bottleneck in therapeutic targets that has been one limiting factor on the rate of therapeutic discovery.[citation needed] However, data indicates that "new targets" as opposed to "established targets" are more prone to drug discovery project failure in general[citation needed] This data corroborates some thinking underlying a pharmaceutical industry trend beginning at the turn of the twenty-first century and continuing today which finds more risk aversion in target selection among multi-national pharmaceutical companies.[citation needed]

This text uses material from Wikipedia, licensed under CC BY-SA